Animal-derived pharmaceutical proteins

Journal of Immunoassay and Immunochemistry

Volumn 30, Issue 3, 2009, Pages 262-290

  Redwan, EL Rashdy M ^a  

^a Universities and Research centers District   (Egypt)

Author keywords

Animals; Anti serum; Derived pharmaceuticals; Gelatin; Insulin; Small peptides; Therapeutic proteins; Transgenic animal

Indexed keywords

ALPHA LATROTOXIN; AMINO ACID; ANTHRAX VACCINE; ANTIDIABETIC AGENT; ANTISERUM; BOTULINUM ANTISERUM; CAPTOPRIL; DESULFATOHIRUDIN; DIPHTHERIA ANTIBODY; ENALAPRIL; ENDOTOXIN ANTIBODY; EPTIFIBATIDE; ERYSIPELAS ANTIBODY; EXENDIN; EXENDIN 4; GAS GANGRENE ANTITOXIN; GELATIN; GLUCAGON LIKE PEPTIDE; HYDROXAMIC ACID; INSULIN; LEPIRUDIN; LISINOPRIL; LOSARTAN; MEASLES ANTIBODY; MONOCLONAL ANTIBODY; OMEGA CONOTOXIN MVIIA; PEPTIDE; RABIES IMMUNOGLOBULIN; TETANUS ANTIBODY; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENOM;

ALZHEIMER DISEASE; ANIMAL CELL CULTURE; ANIMAL PRODUCT; ANTHRAX; ANTICOAGULATION; ARTHROPOD; BIOAVAILABILITY; BIOREACTOR; BIOSAFETY; BONE MARROW CULTURE; BOTULISM; CAMEL; CELL LINE; CHO CELL; CLINICAL TRIAL; CLOSTRIDIUM TETANI; COLITIS; COST; COW; DIABETES MELLITUS; DIPHTHERIA; DRUG COST; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; ECHINODERM; ERYSIPELAS; GAS GANGRENE; GOAT; HEPARIN INDUCED THROMBOCYTOPENIA; HORSE; HUMAN; HYDROGEN BOND; IMMUNOGENICITY; IN VIVO STUDY; INFLUENZA VIRUS A H5N1; INSULIN RELEASE; INTRACTABLE PAIN; INVERTEBRATE; JELLYFISH; LIZARD; MAMMAL; MEASLES; MENINGITIS; MICROBIAL ACTIVITY; MOLECULAR WEIGHT; MOLLUSC; MOUSE; MUSCLE HYPERTONIA; NATURAL SELECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PASSIVE IMMUNIZATION; PHARMACEUTICS; PNEUMONIA; PRIORITY JOURNAL; RABBIT; RABIES; REPTILE; REVIEW; SCORPION; SEA ANEMONE; SERUM SICKNESS; SHEEP; SNAIL; SNAKE; SWINE; TETANUS; THROMBOSIS PREVENTION; TRANSGENIC ANIMAL; TRANSGENIC CATTLE; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES; ANTIBODIES, MONOCLONAL; CATTLE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; GELATIN; HIRUDINS; IMMUNE SERA; IMMUNIZATION, PASSIVE; INSULIN; PHARMACEUTICAL PREPARATIONS; PROTEIN BIOSYNTHESIS; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL; VENOMS;

EID: 68849101000     PISSN: 15321819     EISSN: 15324230     Source Type: Journal    
DOI: 10.1080/15321810903084400     Document Type: Review

References (81)

1. Wedgood, R.J.; Riese, G.R. Touching a cure of an inveterate phrensy by the transfusion of blood. New Engl. J. Med. 1953, 284, 902-904.
2. Hericourt, J.; Richet, Ch. Sur un microbe pyogene et septique (Staphylococcus pyosepticus) et sur la vaccination counter ses effects. Comptes Rend. Acad. Sci. 1888, 107, 960-694.
3. Behring, V.; Kitasato, T. Uber des zustandekommen der Diphtheria-Immunitat und der tetanus-Immunitat bei Thieren. Deutsche Med. Wochensch. 1890, 16, 1113-1114.
4. Ehrtich, P. Experimentelle Untersuchungen uber Immunitat. I. Uber, II. Uber Abrin. Deutsche Med. Wochensch. 1891, 17, 976-979, 1218-1219.
5. Calmette, A. Sure la toxicite du sang de cobra capel, L'immunisation artifi-cielle des animaux contre le venin des serpents, et la therapeutique experimen-tale des morsures venimeuses, Au sujet de l'attenuation des venins par le chauffage et de l'immunisation des animaux contre l'envenimation. Comptes Rend. Soc. Biol. 1894, 45, 11-12, 120-124, 204-205.
6. Phisalix, C.; Bertrand, G. Sure la presence de glandes venimeuses chez les couleuvres et la toxicite du sang de ces animaux, Sure la propriete antitoxique du sang des animaux vaccines contre le venin de vipere, response a M. Calmette, sure les effects de l;ablation des glandes a venin chez la vipere. Comptes Rend. Soc. Biol. 1894, 46, 8-11, 111-113, 124-126, 747-749.
7. Eible, M.M.; Wedgwood, R.J. Intravenous immunoglobulin: A review. Immunodef. Rev. 1989, 1, (suppl. 1) 41.
8. Zinsser, H. Resistance to Infectious Diseases, 4th Ed.; Macmillan: New York, 1931; 75-175.
9. Cenci, F. Alcune esperienze di sieroimmunizzazione e sierterapida nel morbillo. Riv. Clin. Pediatr. 1907, 5, 1017-1025.
10. Nicolle, C.; Conseil, E. Pouvoir preventif du serum d'un malade convalescent de rougeole. Bull. Mem. Soc. Med. Hop. Paris 1918, 42, 336-338.
11. Ehrlich, P. In Collected Papers, Vol III; Himmelweit, F.; Ed.; Pergamon Press: London, 1951; 505-518.
12. Hericourt, J.; Richet, C. Traitement d'un cas de sarcoma par la serotherspie. C. R. Acad. Sci. 1895, 20, 948-950.
13. Theakston, R.D.G.; Smith, D.C. Therapeutic antibodies to snake venoms. In Therapeutic Antibodies; Landon, J.; Chard, T.; Eds.; Springer-Verlag: London, 1995; 109-133.
14. Casadevall, A.; Scharff, M.D. Return to the past: The case for antibody-based therapies in infectious diseases. C.I.D. 1995, 21, 150-161.
15. Theakston, R.D.G.; Warrell, D.A. Antivenoms: A list of hyperimmune sera currently availiable for the treatment of envenoming by bits and stings. Toxicon. 1991, 29, 1419-1470.
16. Heath, A.J. Immunotherapy for drug toxicity. In Therapeutic Antibodies; Landon, J.; Chard, T.; Eds.; Springer-Verlag: London, 1995; 89-108.
17. 2 in mice. Resp. Res. 2006, 7, 1-7.
18. Wilde, H.; Thipkong, P.; Sitprija, V.; Chaiyabutr, N. Heterologous antisera and antivenins are essential biologicals: Perspectives on a worldwide crisis. Ann. Int. Med. 1996, 125, 233-236.
19. Prin Mathieu, C.; Renoult, E.; Kennel De March, A.; Bene, M.C.; Kessler, M.; Faure, G.C. Serum anti-rabbit and anti-horse IgG, IgA, and IgM in kidney transplant recepients. Nephrol. Dial. Transplant. 1997, 12, 2133-2139.
20. Redwan, E.R. Cumulative updating of approved biopharmaceuticals. Human Antibodies 2007, 16, 137-158.
21. Thibaudin, D.; Alamartine, E.; Filippis, J.P. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocytes globulin. Nephrol Dial. Transplant. 1998, 13, 711-715.
22. Theakston, R.D.G.; Warrell, D.A.; Griffiths, E. Report of a WHO workshop on the standardization and control of antivenom. Toxicon 2003, 41, 541-557.
23. 2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. C.I.D. 1996, 23, 337-340.
24. Kalluri, P.; Crowe, C.; Reller, M. An outbreak of foodborne botulism associated with food sold at a salvage store in Texas. C.I.D. 2003, 37, 1490-1495.
25. Dart, R.C.; McNally, J. Efficacy, safety, and use of antivenom. Ann. Emerg. Med. 2001, 37, 185-188.
26. Abel, J.J. Crystalline insulin. Proc. Natl. Acad. Sci. USA 1926, 12, 132-136.
27. Sanger, F.; Thompson, E.O.; Kitai, R. The amide groups of insulin. Biochem. J. 1955, 59, 509-518.
28. Volfin, P.; Chambaut, M.; Eboué-bonis, E. Biological Activity of Natural and Synthetic Insulin A-chain Preparations on the Isolated Rat Diaphragm. Nature 1964, 203, 408-409.
29. Steiner, D.F.; Cunningham, D.; Spigelman, L. Insulin biosynthesis: evidence for a precursor. Science 1967, 157, 697-700.
30. Granner, D.K. Hormones of the pancreas and GI tract. In Haper's Biochemistry; Murray, R.K.; Mayes, P.A.; Granner, D.K.; Rodwell, V.W.; Eds.; Appleton & Lange: California, 1990; 530-545.
31. Redwan, E.R.; Matar, S.M.; El-Aziz, G.; Serour, E.A. Synthesis of the human insulin gene: Protein expression, scaling up and bioactivity. Prep. Biochem. Biotechnol. 2008, 38, 1-16.
32. Ramasamy, I. The risk of accidental transmission of transmissible spongi-form encephalopathy: identification of emerging issues. Publ. Hlth. 2004, 118, 409-420.
33. Werten, M.A.T.; Wisselink, W.H.; Bosch, T.J. Secreted production of a custom-digested, highly hydrophilic gelatin in Pichia pastoris. Protein Eng. 2001, 14, 447-454.
34. Torres-Larios, A.; Gurrola, G.B.; Zamudio, F.Z.; Possani, L.D. Hadrurin a new antimicrobial peptide from the venom of the scorpion Hadrurus aztecus. Eur. J. Biochem. 2000, 267, 5023-5031.
35. Weitz, J.I.; Crowther, M.A. New anticoagulants: Current status and future potential. Am. J. Cadiovasc. Drugs 2003, 3, 201-209.
36. Zhou, X.D.; Jin, Y.; Chen, R.Q.; Lu, Q.M.; Wu, J.B.; Wang, W.Y. Purification, cloning and biological characterization of a novel disintegrin from Trimeresurus jerdonii venom. Toxicon 2004, 43, 69-75.
37. Sewald, N.; Jakubke, H.-J. Peptide and Protein Design, Pseudopeptides, and Peptidomimetics-7. In Peptides: Chemistry and Biology; Wiley-VCH Verlag GmbH., 2002.
38. Rich, D.H. Compr. Med. Chem. 1990, 2, 400.
39. Turbanti, L.; Cerbai, G.; Di Bugno, C. 1,2-Cyclomethylenecarboxylic monoamide hydroxamic derivatives. A novel class of non-amino acid angiotensin converting enzyme inhibitors. J. Med. Chem. 1993, 36, 699-707.
40. Beeton, C.; Gutman, G.A.; George Chnady, K. Targets and Therapeutic properties of venom peptides. In Handbook of biologically active peptides; Kastin, A.J.; Ed.; Academic Press, 2006; 403-414.
41. Joy, S.V.; Rodgers, P.T.; Scates, A.C. Incretin mimetics as emerging treatments for type 2 diabetes. Ann. Pharmacother. 2005, 39, 110-118.
42. Marenah, L.; Shaw, C.; Orr, D.F.; McClean, S.; Flatt, P.R.; Abdel-Wahab, Y.H. Isolation and characterisation of an unexpected class of insulinotropic peptides in the skin of the frog Agalychnis litodryas. Regul. Pept. 2004, 120, 33-38.
43. Lewis, R.J.; Garcia, M.L. Therapeutic potential of venom peptides. Nat. Rev. Drug Discov. 2003, 2, 790-802.
44. Maraganore, G.M.; Bourdon, P.; Jablonski, J. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochem. 1990, 29, 7095-7101.
45. Greinacher, A.; Eichler, P.; Lubenow, N. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999, 100, 587-593.
46. Greinacher, A.; Janssens, U.; Berg, G. Heparin-induced thrombocytopenia with thromboembolitic complications: Meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic a PTT range. Blood 2000, 96, 846-851.
47. Warkentin, T.E.; Kelton, J.G. A 14-year study of heparin-induced thrombo-cytopenia. Am. J. Med. 1996, 101, 502-507.
48. Matheson, A.J.; Goa, K.L. Desirudin: A review of its use in the management of thrombotic disorders. Drugs 2000, 60, 679-700.
49. Olivera, B.M. Conus snail venom peptides. In Handbook of Biologically Active Peptides; Kastin, A.J.; Ed.; Academic Press, 2006; 381-388.
50. Olivera, B.M.; River, J.; Clark, C. Diversity of conus polypeptides. Science 1990, 249, 257-263.
51. Mathur, V.S. Neuronal N-type calcium channels: New prospect in pain therapy. Pharm News 1998, 5, 25-29.
52. Prialt (fact sheet), San Diego, CA, Elan Pharmaceuticals, 2005.
53. Shulman, M.; Wilde, C.D.; Kohler, G. A better cell line for making hybridomas secreting specific antibodies. Nature 1978, 276, 269-270.
54. Galfre, G.; Milstein, C. Preparation of monoclonal antibodies: Strategies and procedures. Meth. Enzymol. 1981, 73, 3-46.
55. Bebbington, C.R.; Renner, G.; Thomson, S. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology 1992, 10, 169-175.
56. Bebbington, C.R. Expression of antibody genes in nonlymphoid mammalian cells. Methods 1991, 2, 136-145.
57. Mountain, A.; Adair, J.R. Engineering antibodies for therapy. Biotechnol. Genetic Eng. Rev. 1992, 10, 1-141.
58. Harris, W.J. Humanized monoclonal antibodies for in vivo use. Animal Cell Biotechnol. 1994, 6, 259-279.
59. Martin, M.J. Transgenic animals: Secreted products. In Encyclopedia of Animal Science; Pond, W.; Bell, A.; Eds.; Marcel Dekker, Inc.: New York, 2004; 843-846.
60. Dunn, D.A.; Kooyman, D.L.; Pinkert, C.A. Transgenic animals and their impact on the drug discovery industry. D.D.T. 2005, 10, 757-767.
61. Kues, W.A.; Niemann, H. The contribution of farm animals to human health. Trends Biotechnol. 2004, 22, 286-294.
62. Keefer, C.L. Production of bioproducts through the use of transgenic animal models. Animal Reprod. Sci. 2004, 82-83, 5-12.
63. Nikolo, Z.L.; Woodard, S.L. Downstream processing of recombinant proteins from transgenic feedstock. Curr. Opin. Biotechnol. 2004, 15, 479-486.
64. Lillico, S.G.; McGrew, M.J.; Sherman, A.; Sang, H.M. Transgenic chicken as bioreactor for protein-based drugs. D.D.T. 2005, 10, 191-196.
65. Verity, E.E.; Williams, L.A.; Haddad, D.N. Broad neutralization and complement-mediated lysis of HIV-1 by HRG214, a novel caprine anti-HIV-1 polyclonal antibody. AIDS 2006, 20, 505-515.
66. Redwan, E.R.; Fahmy, A.; EL-Hanafy, A.; Abd EL-Baky, N.; Sallam, S.A. Ovine anti-rabies antibody production and evaluation. Comp. Immunol. Microbiol. Infect. Dis. 2008, Jan 31. [Epub ahead of print]
67. 2 fractionated with ammonium sulfate and caprylic acid. J. Immunoassay Immuno-chem. 2006, 27, 319-329.
68. Weltzin, R.; Month, T.P. Intranasal antibody prophylaxis for protection against viral disease. Clin. Microbial. Rev. 1999, 12, 383-393.
69. Walsh, G. Biopharmaceuticas: Biochemsitry and Biotechnology, 2nd Ed.; John Wiley & Sons Ltd.: England, 2003.
70. Lien, S.; Lowman, H.B. Therapeutic peptides. Trends Biotech. 2003, 21, 556-562.
71. Sato, A.; Viswanathan, M.; Kent, R.B.; Wood, C.R. Therapeutic peptides: Technological advances driving peptides into development. Curr. Opin. Biotechnol. 2006, 17, 638-642.
72. Landner, R.C.; Sato, A.K.; Gorzelandy, J.; De Souza, M. Phage display-derived peptides as therapeutic alternatives to antibodies. D.D.T. 2004, 9, 525-529.
73. Zetler, G. Caerulein and its analogues: Neuropharmacological properties. Peptides 1985, 6 (Suppl), 33-46.
74. Zelezetsky, I.; Pag, U.; Antcheva, N.; Sahl, H.G.; Tossi, A. Identification and optimization of an antimicrobial peptide from the antivenom toxin pilosulin. Arch. Biochem. Biophys. 2005, 434, 358-364.
75. Yang, R.-S.; Tang, C.-H.; Chuang, W.-J. Inhibition of tumor formation by snake venom disintegrin. Toxicon 2005, 45, 661-669.
76. Miljanich, G.P. Ziconotide: Neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 2004, 11, 3029-3040.
77. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389-395.
78. Bogin, O. Venom peptides and their mimetics as potential drugs. Modulator 2005, 19, 14-20 (www.almone.com).
79. Wang, C.Z.; Chi, C.W. Conus peptides - a rich pharmaceutical treasure. Acta Biochim. Biophys. Sin. (Shanghai) 2004, 36, 713-723.
80. Livett, B.G.; Sandall, D.W.; Keays, D. Therapeutic applications of conotox-ins that target the neuronal nicotinic acetylcholine receptor. Toxicon 2006, 48, 810-829.
81. Andersson, L.; Blomberg, L.; Flegel, M. Large-scale synthesis of peptides. Biopolymers 2000, 55, 227-250.